



Neuren Pharmaceuticals Limited
Level 2, 57 Wellington Street
Freemans Bay, Auckland, New Zealand
office: +64 9 529 3940
fax: +64 9 361 7981
enquiries@neurenpharma.com
www.neurenpharma.com

18 November 2009

The Company Announcements Office
ASX Limited

For Release to the Market

Notice under section 708A(5)(e) of the Corporations Act

On 18 November 2009, the Company announced the issue of 14,070,669 fully paid ordinary shares (new shares). Allotment of the new shares was completed on 18 November 2009.

The Company relies on case 1 in section 708A(5) of the Corporations Act 2001 (Act) in respect of the issue of the new shares.

The Company gives notice under paragraph (5)(e) of section 708A of the Act that:

1. The Company issued the new shares without disclosure to the recipient under Part 6D.2 of the Act;
2. As at the date of this notice the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act (as applicable to the Company); and
 - (b) section 674 of the Act; and
3. As at the date of this notice there is no excluded information (as defined in section 708A(7) of the Act) which is required to be disclosed by the Company other than that Neuren is in discussions with a number of parties concerning an equity placement. These discussions are unrelated to the convertible loan agreement and the proposed investors of the US\$1million announced today. With regard to these other discussions, no agreement has been reached as to terms, including price. There is no guarantee that the discussions will culminate in a binding placement agreement. Neuren will make a further announcement if agreement is reached.

Yours sincerely

A handwritten signature in black ink, appearing to read "Rob Turnbull".

Mr Rob Turnbull
Chief Financial Officer